Azenta, Inc. (AZTA)
NASDAQ:AZTA
Want to see AZTA full AI Analyst Report?
AZTA Stock Chart & Stats
$28.18
-$0.47(-0.91%)
At close: 4:00 PM EST
$28.18
-$0.47(-0.91%)
Day’s Range― - ―
52-Week Range$19.87 - $41.73
Previous CloseN/A
Volume88.55K
Average Volume (3M)965.29K
Market Cap
$1.16B
Enterprise Value$886.43M
Total Cash (Recent Filing)$412.05M
Total Debt (Recent Filing)$108.92M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 11, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding46,061,527
10 Day Avg. Volume770,217
30 Day Avg. Volume965,289
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda16.44
Forecast
1Y Price Target
$36.00Price Target Upside27.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.78
Revenue Forecast (FY)$622.50M
Bulls Say, Bears Say
Bulls Say
Mergers & AcquisitionsAnalyst expects the company to pursue mergers and acquisitions in sample preparation and gene synthesis to expand capabilities and drive margin accretion.
Operational RestructuringOngoing restructuring and regionalization of the multiomics business are expected to reduce costs and enable margin expansion and a return to growth.
Revenue Mix And Geographic GrowthStrength in next-generation sequencing, biorepository services, and international markets should diversify revenue and support top-line growth.
Bears Say
Core Product DemandWeakness in capital-intensive offerings such as automated stores and cryogenic systems may weigh on organic revenue growth.
Product Quality IssuesPersistent quality problems in later-stage automated store projects have increased rework costs and continue to pressure profit margins.
Profitability And Cost PressuresLower gross margins and higher operating costs caused an earnings shortfall, and management indicated sales and margin improvements will be phased, which could stretch pressure on profitability.
Azenta News
AZTA FAQ
What was Azenta, Inc.’s price range in the past 12 months?
Azenta, Inc. lowest stock price was $19.87 and its highest was $41.73 in the past 12 months.
What is Azenta, Inc.’s market cap?
Azenta, Inc.’s market cap is $1.16B.
When is Azenta, Inc.’s upcoming earnings report date?
Azenta, Inc.’s upcoming earnings report date is May 11, 2026 which is in 12 days.
How were Azenta, Inc.’s earnings last quarter?
Azenta, Inc. released its earnings results on Feb 04, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.138 by -$0.048.
Is Azenta, Inc. overvalued?
According to Wall Street analysts Azenta, Inc.’s price is currently Undervalued.
Does Azenta, Inc. pay dividends?
Azenta, Inc. pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta, Inc. dividends here
What is Azenta, Inc.’s EPS estimate?
Azenta, Inc.’s EPS estimate is 0.13.
How many shares outstanding does Azenta, Inc. have?
Azenta, Inc. has 46,061,527 shares outstanding.
What happened to Azenta, Inc.’s price movement after its last earnings report?
Azenta, Inc. reported an EPS of $0.09 in its last earnings report, missing expectations of $0.138. Following the earnings report the stock price went down -22.812%.
Which hedge fund is a major shareholder of Azenta, Inc.?
Currently, no hedge funds are holding shares in AZTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (27.75% Upside)
$36.00 (27.75% Upside)
Blogger Sentiment
Bullish
AZTA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 897.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
-3.39%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Azenta, Inc.
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
AZTA Company Deck
AZTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: management reaffirmed full-year guidance, highlighted strong cash, active capital allocation (including a $250M buyback authorization), and clear operational initiatives (ABS, Kaizen, regionalization) that support a planned margin and revenue ramp in the back half. However, near-term results show meaningful margin compression (gross margin down ~360 bps, adjusted EBITDA margin down ~230 bps), automated store quality remediation costs ($3M–$5M), North American softness and a meaningful decline in Sanger sequencing. Given the mix of strategic positives and notable near-term headwinds, the tone is cautiously optimistic but tempered by execution and macro risks.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$36.00
▲(27.75% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
35.80% Mutual Funds
11.42% Other Institutional Investors
23.02% Public Companies and
Individual Investors